Scientific Reports
Cure8 research brief
Why This Matters
Reliable, high-throughput lab methods are a prerequisite for therapeutic drug monitoring (TDM). For people with IBD on JAK inhibitors, validated assays can enable exposure measurement needed for future precision dosing and research into drug levels and outcomes.
Who Should Pay Attention
Clinicians treating IBD with JAK inhibitors, laboratory scientists developing TDM assays, researchers studying drug exposure–response relationships, and adult patients on JAKi therapy interested in TDM research.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthMetadata only
What To Know
This Scientific Reports paper presents a fully validated µSPE-HPLC-MS/MS laboratory method for quantifying serum concentrations of Janus kinase inhibitors (JAKis) used in IBD care. The protocol was optimized and validated following FDA guidelines and tested in a small real-world cohort of 27 patients receiving tofacitinib, upadacitinib, or filgotinib.
The workflow uses microelution solid-phase extraction and triple-quadrupole mass spectrometry to measure total drug levels, aims to be high-throughput and greener in solvent use, and includes concentration-matched verification against clinical samples.
The authors propose the method as a platform for therapeutic drug monitoring (TDM) and future precision-dosing research in IBD.
The study includes opportunistic serial sampling that characterized exposure variability and detected treatment interruptions in the small cohort; it does not report therapeutic targets or clinical outcome thresholds for JAKi dosing. The article is a methods/validation study rather than a trial of dosing strategies or efficacy.
Keep In Mind
This is a methods and validation paper with a small pilot sample (27 patients) showing assay performance and feasibility. It does not establish therapeutic drug targets or change clinical care by itself; further clinical studies are needed to link measured concentrations to outcomes.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationScientific Reports
PublisherSpringer Science and Business Media LLC
AuthorsIvana Cizmarova, Peter Bystricky, Zuzana Zelinkova +1 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedAug 18, 2026, 12:00 AM
Content availableMetadata only
Funding disclosed by the source: the EU NextGenerationEU through the Recovery and Resilience Plan for Slovakia, award 09I03-03-V04-00157
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Safety and Efficacy of a STOPping Strategy Versus Classical Maintenance Dose of JAK Inhibitors in Deep Remission Patients With Ulcerative Colitis
This trial tests whether people with UC in deep remission can safely stop JAK inhibitor therapy — potentially reducing long-term exposure and associated safety concerns while preserving disease control and quality of...
Anti-TNF, Pan-JAK, and JAK1-Selective Inhibition Differentially Alter Mechanisms of Flow-Mediated Dilation in Human Microvessels.
People with IBD already face higher cardiovascular risk; drugs used to treat IBD (anti-TNF and JAK inhibitors) may differently affect small-vessel endothelial function, a possible contributor to heart and vascular...
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Superior Effectiveness of Upadacitinib Over Tofacitinib and Ustekinumab in Bio-Exposed Ulcerative Colitis: The TRIDENT-UC Study.
For people with ulcerative colitis who have already tried and failed one or more advanced therapies, this study suggests upadacitinib may lead to higher rates of steroid-free clinical remission and endoscopic healing...